Global Immuno-oncology Drugs Market Insights and Forecast to 2026


Immuno-oncology Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Immuno-oncology Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.

Segment by Type, the Immuno-oncology Drugs market is segmented into


  • Immune Checkpoint Inhibitors
  • Monoclonal Antibodies
  • Cytokine-Based Immunotherapy
  • Cancer Vaccines
  • CAR-T Cell Therapy

Segment by Application, the Immuno-oncology Drugs market is segmented into

  • Hospitals
  • Pharmacies
  • Online Pharmacies

Regional and Country-level Analysis

The Immuno-oncology Drugs market is analysed and market size information is provided by regions (countries).

The key regions covered in the Immuno-oncology Drugs market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.

Competitive Landscape and Immuno-oncology Drugs Market Share Analysis

Immuno-oncology Drugs market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Immuno-oncology Drugs business, the date to enter into the Immuno-oncology Drugs market, Immuno-oncology Drugs product introduction, recent developments, etc.

The major vendors covered:

  • Amgen, Inc
  • AstraZeneca, Plc
  • Bristol-Myers Squibb
  • Celgene Corporation
  • Eli Lilly and Company
  • Merck & Co.
  • Hoffmann-La Roche AG
  • Johnson & Johnson
  • Novartis International AG
  • AbbVie, Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • EMD Serono, Inc.
  • Gilead Sciences Inc.
  • Prometheus Therapeutics & Diagnostics
  • Aduro BioTech
  • Galena Biopharma
  • Bavarian Nordic
  • Celldex Therapeutics
  • ImmunoCellular Therapeutics
  • Incyte

Table of content

1 Study Coverage
1.1 Immuno-oncology Drugs Product Introduction
1.2 Market Segments
1.3 Key Immuno-oncology Drugs Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Immuno-oncology Drugs Market Size Growth Rate by Type
1.4.2 Immune Checkpoint Inhibitors
1.4.3 Monoclonal Antibodies
1.4.4 Cytokine-Based Immunotherapy
1.4.5 Cancer Vaccines
1.4.6 CAR-T Cell Therapy
1.5 Market by Application
1.5.1 Global Immuno-oncology Drugs Market Size Growth Rate by Application
1.5.2 Hospitals
1.5.3 Pharmacies
1.5.4 Online Pharmacies
1.6 Study Objectives
1.7 Years Considered

2 Executive Summary
2.1 Global Immuno-oncology Drugs Market Size, Estimates and Forecasts
2.1.1 Global Immuno-oncology Drugs Revenue 2015-2026
2.1.2 Global Immuno-oncology Drugs Sales 2015-2026
2.2 Global Immuno-oncology Drugs, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Immuno-oncology Drugs Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Immuno-oncology Drugs Retrospective Market Scenario in Revenue by Region: 2015-2020

3 Global Immuno-oncology Drugs Competitor Landscape by Players
3.1 Immuno-oncology Drugs Sales by Manufacturers
3.1.1 Immuno-oncology Drugs Sales by Manufacturers (2015-2020)
3.1.2 Immuno-oncology Drugs Sales Market Share by Manufacturers

276 5th Avenue, New York , NY 10001,United States
International: (+1) 646 781 7170 / +91 8087042414

Follow Us On linkedin :-